NCT07041060View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of Eolo in Patients With NERD

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 30, 2025

Primary Completion Date

May 30, 2025

Study Completion Date

May 30, 2025

Conditions
Non-erosive Reflux DiseaseReflux Disease, Gastro-EsophagealNutraceutical
Interventions
DIETARY_SUPPLEMENT

EOLO

Eolo, a nutraceutical blend of sodium alginate, sodium bicarbonate, palmitoylethanolamide (PEA), and herbal extracts

DRUG

PPI (proton pump inhibitor)

Received a half-dose of PPIs for 24 weeks

DIETARY_SUPPLEMENT

Group C: Eolo

Eolo, a nutraceutical blend of sodium alginate, sodium bicarbonate, palmitoylethanolamide (PEA), and herbal extracts for 24 weeks

Trial Locations (1)

40138

DIMEC, Bologna

All Listed Sponsors
lead

University of Bologna

OTHER